# Narration and storyboard draft: Berberine and Glycemic Control

Authored draft, approximately 60–90 seconds; no rendered video claimed.

Berberine is often discussed as if glucose control, weight loss and anti-aging stacks were one claim. Our review separates them. The best verified ordinary-berberine trial studied people with newly diagnosed type2 diabetes for twelve weeks. HbA1c fell in both groups, but berberine produced about four-tenths of a percentage point more improvement than placebo. Every participant first received the same antibiotic run-in, an important limit when transferring the result to usual care. This supports a short-term glycemic treatment effect at HSEF Delta with moderate confidence. It does not identify one necessary human mechanism. A different formulation containing ursodeoxycholic acid also improved HbA1c, but cannot be treated as the same product. In a large diabetes-free obesity trial, ordinary berberine did not reduce visceral or liver fat. No examined direct trial establishes modern GLP-1 equivalence or validates the exact berberine, glutathione and NMN stack. The next useful study tests chemically verified berberine under stable diabetes care, follows durability and interactions, and measures meaningful clinical outcomes separately.

1. Show the exact claim, grade and confidence.
2. Show selected publication milestones; label experimental systems and clinical endpoints.
3. Contrast the strongest result with its source-specific limitation.
4. End with the boundary experiment and primary-source links.

Use authored schematics; do not depict Consensus meters as causal confidence or reproduce publisher graphics without appropriate permission.